BeiGene Ltd (SH: 688235), trading at 279.00 yuan per share with a market capitalization of 430.298 billion yuan, released its semi-annual report for 2026 on August 26. The report reveals that the company achieved total operating revenue of 22.220 billion yuan in the first half of 2026, representing a year-on-year increase of 26.8%. Net profit attributable to shareholders of the listed company reached 3.271 billion yuan, surging 627.1% compared to the same period last year. Product revenue totaled 21.797 billion yuan, up 25.6% year-on-year.

According to the interim report, the 25.6% growth in product revenue to 21.797 billion yuan was primarily driven by increased sales of BRUKINSA, Amgen-licensed products, and TEVIMBRA. Among these, the core product BRUKINSA achieved global sales of 16.127 billion yuan, up 28.7% year-on-year, with U.S. market sales reaching 11.390 billion yuan, an increase of 27.2%. TEVIMBRA generated global sales of 2.984 billion yuan, growing 12.9%, while Amgen-licensed products contributed 2.065 billion yuan in sales, up 19.6%.

On the profitability front, the company's total profit for the first half reached 4.083 billion yuan, soaring 412.4% year-on-year. Net profit attributable to shareholders stood at 3.271 billion yuan, up 627.1%, while net profit excluding non-recurring gains and losses was 2.918 billion yuan, skyrocketing 1017.6%. After adjusting for non-cash items such as share-based compensation expenses, depreciation, and amortization, adjusted operating profit reached 6.508 billion yuan, up 101.9%, and adjusted net profit was 5.863 billion yuan, representing a 127.0% year-on-year increase. The company attributed this strong performance to product revenue growth and improved operational efficiency driven by cost management.

In terms of cash flow, net cash generated from operating activities in the first half amounted to 4.439 billion yuan, a substantial 172.1% increase year-on-year. Research and development investment totaled 7.953 billion yuan during the period, accounting for 35.79% of operating revenue. As of the end of the reporting period, total assets reached 62.499 billion yuan, up 9.1% from the beginning of the period, while net assets attributable to shareholders of the listed company stood at 35.427 billion yuan, increasing 15.6%.

As a globally leading innovative oncology company, BeiGene is dedicated to developing novel anti-tumor drugs for cancer patients worldwide. The company is listed on three major exchanges simultaneously — the Nasdaq Global Select Market, the Hong Kong Stock Exchange, and the STAR Market of the Shanghai Stock Exchange — making it the first biotech company to achieve this triple listing. The company's independently developed BTK inhibitor BRUKINSA is the most broadly approved BTK inhibitor globally, having received approval in over 80 markets worldwide. TEVIMBRA, the cornerstone of the company's solid tumor portfolio, has been approved in more than 50 markets. Additionally, BeiGene maintains a robust pipeline and commercialized products including BRUKYNSA.

Looking at share price performance, BeiGene's stock has shown a volatile trend this year. The stock began the year near the 300 yuan level, briefly surged to around 320 yuan in mid-January, and subsequently experienced a pullback.

Disclaimer: This article's content and data are for reference only and do not constitute investment advice. Please verify before use. Any actions taken based on this information are at your own risk.